ENDRA Life Sciences Inc. provided earnings guidance for the quarter ended March 31, 2024. The company expects no revenue for the quarter ended March 31, 2024 and did not have any revenue for the quarter ended March 31, 2023. The company expects to record a net loss of approximately $2.8 million for the quarter ended March 31, 2024, compared to a net loss of approximately $2.9 million for the quarter ended March 31, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2822 USD | +0.39% | -8.11% | -86.69% |
14/05 | Transcript : ENDRA Life Sciences Inc., Q1 2024 Earnings Call, May 14, 2024 | |
14/05 | Endra Life Sciences Inc. Announces Impairment Charges for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-86.69% | 3.11M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+44.98% | 40.65B | |
-10.87% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- NDRA Stock
- News ENDRA Life Sciences Inc.
- ENDRA Life Sciences Inc. Provides Earnings Guidance for the Quarter Ended March 31, 2024